Morristown, NJ (USA), 5 March 2019 – Lonza has today announced the launch of its new performance nutrition brand, Oceanix™ in the U.S.A and Canada. The unique phytoplankton ingredient is sustainably sourced from the ocean and meets rising demand for natural, non-GMO and vegan supplement products.
Containing highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals, the Oceanix™ ingredient offers potential benefits for physical performance and an increased physiological response against oxidative stress to aid recovery in a small, concentrated dose.
Shane Durkee, Vice President, Platform Innovation, R&D, Lonza Consumer Health, commented: “Our goal is to consistently challenge the status quo by always developing innovative, science-backed products that meet the needs of our customers and our consumers. With its vegan origins, the Oceanix™ ingredient brings sports performance and wellness benefits together, appealing to a new set of consumers.”
He added, “More and more consumers are pushing their physical performance, both in terms of intensity and the duration of activity. These consumers want effective performance nutrition to support performance and recovery that’s also clean label, non-GMO, high quality and clinically studied. Oceanix™ phytoplankton ingredient delivers on these consumer demands in a small, effective, once-a-day 25 mg dose.”
Produced using patent-pending technology, the Oceanix™ brand is suitable for use in a variety of sports nutrition applications, including dietary supplements, bars, drinks and powders.
More information is available about how manufacturers can develop performance nutrition products containing Oceanix™ Marine Phytoplankton on the Lonza Consumer Health & Nutrition website at www.lonza.com or at the Natural Products Expo West booth 4005.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.